A systematic review of the health economic consequences of quadrivalent influenza vaccination

de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crepey P, Pitman R, Wilschut JC, Postma MJ (2017)
Expert Review of Pharmacoeconomics & Outcomes Research 17(3): 249-265.

Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
; ; ; ; ; ; ; ;
Abstract / Bemerkung
Background: Quadrivalent influenza vaccines (QIVs) contain antigens derived from an additional influenza type B virus as compared with currently used trivalent influenza vaccines (TIVs). This should overcome a potential reduced vaccine protection due to mismatches between TIV and circulating B viruses. In this study, we systematically reviewed the available literature on health economic evaluations of switching from TIV to QIV.Areas covered: The databases of Medline and Embase were searched systematically to identify health economic evaluations of QIV versus TIV published before September 2016.A total of sixteen studies were included, thirteen cost-effectiveness analyses and three cost-comparisons.Expert commentary: Published evidence on the cost-effectiveness of QIV suggests that switching from TIV to QIV would be a valuable intervention from both the public health and economic viewpoint. However, more research seems mandatory. Our main recommendations for future research include: 1) more extensive use of dynamic models in order to estimate the full impact of QIV on influenza transmission including indirect effects, 2) improved availability of data on disease outcomes and costs related to influenza type B viruses, and 3) more research on immunogenicity of natural influenza infection and vaccination, with emphasis on cross-reactivity between different influenza B viruses and duration of protection.
Expert Review of Pharmacoeconomics & Outcomes Research


de Boer PT, van Maanen BM, Damm O, et al. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research. 2017;17(3):249-265.
de Boer, P. T., van Maanen, B. M., Damm, O., Ultsch, B., Dolk, F. C. K., Crepey, P., Pitman, R., et al. (2017). A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research, 17(3), 249-265. doi:10.1080/14737167.2017.1343145
de Boer, P. T., van Maanen, B. M., Damm, O., Ultsch, B., Dolk, F. C. K., Crepey, P., Pitman, R., Wilschut, J. C., and Postma, M. J. (2017). A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 17, 249-265.
de Boer, P.T., et al., 2017. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research, 17(3), p 249-265.
P.T. de Boer, et al., “A systematic review of the health economic consequences of quadrivalent influenza vaccination”, Expert Review of Pharmacoeconomics & Outcomes Research, vol. 17, 2017, pp. 249-265.
de Boer, P.T., van Maanen, B.M., Damm, O., Ultsch, B., Dolk, F.C.K., Crepey, P., Pitman, R., Wilschut, J.C., Postma, M.J.: A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research. 17, 249-265 (2017).
de Boer, Pieter T., van Maanen, Britt M., Damm, Oliver, Ultsch, Bernhard, Dolk, Franklin C. K., Crepey, Pascal, Pitman, Richard, Wilschut, Jan C., and Postma, Maarten J. “A systematic review of the health economic consequences of quadrivalent influenza vaccination”. Expert Review of Pharmacoeconomics & Outcomes Research 17.3 (2017): 249-265.

9 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.
Yun JW, Choi MJ, Shin GS, Lim JO, Noh JY, Kim YK, Song JY, Kim WJ, Choi SE, Cheong HJ., PLoS One 14(1), 2019
PMID: 30682030
Circulation of influenza A and B in the Czech Republic from 2000-2001 to 2015-2016.
Havlickova M, Druelles S, Jirincova H, Limberkova R, Nagy A, Rasuli A, Kyncl J., BMC Infect Dis 19(1), 2019
PMID: 30764763
The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, Barr IG, Postma MJ, Milne GJ., Vaccine 36(7), 2018
PMID: 29373192
Meditation or exercise for preventing acute respiratory infection (MEPARI-2): A randomized controlled trial.
Barrett B, Hayney MS, Muller D, Rakel D, Brown R, Zgierska AE, Barlow S, Hayer S, Barnet JH, Torres ER, Coe CL., PLoS One 13(6), 2018
PMID: 29933369
Cell culture-derived flu vaccine: Present and future.
Pérez Rubio A, Eiros JM., Hum Vaccin Immunother 14(8), 2018
PMID: 29672213
Increasing influenza and pneumococcal vaccine uptake in the elderly: study protocol for the multi-methods prospective intervention study Vaccination60.
Betsch C, Rossmann C, Pletz MW, Vollmar HC, Freytag A, Wichmann O, Hanke R, Hanke W, Heinemeier D, Schmid P, Eitze S, Weber W, Reinhardt A, Küpke NK, Forstner C, Fleischmann-Struzek C, Mikolajetz A, Römhild J, Neufeind J, Rieck T, Suchecka K, Reinhart K., BMC Public Health 18(1), 2018
PMID: 30012141
Adult Immunization - Need of the Hour.
Jairaj A, Shirisha P, Abdul MSM, Fatima U, Tiwari RVC, Moothedath M., J Int Soc Prev Community Dent 8(6), 2018
PMID: 30596036
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E., Pharmacoeconomics 36(12), 2018
PMID: 30251078
Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M., BMC Med 15(1), 2017
PMID: 28882149

60 References

Daten bereitgestellt von Europe PubMed Central.

The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB., Vaccine 25(27), 2007
PMID: 17544181
The rationale for quadrivalent influenza vaccines.
Ambrose CS, Levin MJ., Hum Vaccin Immunother 8(1), 2012
PMID: 22252006
Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?
Caini S, Andrade W, Badur S, Balmaseda A, Barakat A, Bella A, Bimohuen A, Brammer L, Bresee J, Bruno A, Castillo L, Ciblak MA, Clara AW, Cohen C, Cutter J, Daouda C, de Lozano C, De Mora D, Dorji K, Emukule GO, Fasce RA, Feng L, Ferreira de Almeida WA, Guiomar R, Heraud JM, Holubka O, Huang QS, Kadjo HA, Kiyanbekova L, Kosasih H, Kusznierz G, Lara J, Li M, Lopez L, Mai Hoang PV, Pessanha Henriques CM, Matute ML, Mironenko A, Moreno B, Mott JA, Njouom R, Nurhayati , Ospanova A, Owen R, Pebody R, Pennington K, Puzelli S, Quynh Le MT, Razanajatovo NH, Rodrigues A, Rudi JM, Tzer Pin Lin R, Venter M, Vernet MA, Wangchuk S, Yang J, Yu H, Zambon M, Schellevis F, Paget J; Global Influenza B Study, Kusznierz G, Owen R, Wangchuk S, Marins JR, Vernet G, Fasce R, Luzhao F, Clara AW, Bruno A, Clara AW, Maria Zambon , Clara AW, Clara AW, Kosasih H, Rizzo C, Kadjo HA, Muratbayeva G, Mott J, Heraud JM, Barakat A, Huang S, Clara AW, Clara AW, Nunes B, Lee V, Venter M, Ciblak MA, Mironenko A, Bresee J, Mai le TQ., PLoS ONE 11(3), 2016
PMID: 27031105
Prevention and Control of Seasonal Influenza with Vaccines.
Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, Jernigan DB, Bresee JS., MMWR Recomm Rep 65(5), 2016
PMID: 27560619

Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination.
Quinn E, Jit M, Newall AT., Expert Rev Pharmacoecon Outcomes Res 14(3), 2014
PMID: 24734967

Tisa, J Prev Med Hyg 57(), 2016
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E., Pharmacoeconomics 31(5), 2013
PMID: 23529207
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users.
Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL., Pharmacoeconomics 34(4), 2016
PMID: 26660529
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J, Clarke M, Cook D, D'Amico R, Deeks J, Devereaux PJ, Dickersin K, Egger M, Ernst E, Gotzsche PC, Grimshaw J, Guyatt G, Higgins J, Ioannidis JP, Kleijnen J, Lang T, Liberati A, Magrini N, McNamee D, Moja L, Moher D, Mulrow C, Napoli M, Oxman A, Pham B, Rennie D, Sampson M, Schulz KF, Shekelle PG, Tetzlaff J, Tovey D, Tugwell P., PLoS Med. 6(7), 2009
PMID: 19621072
Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
Chit A, Roiz J, Briquet B, Greenberg DP., Vaccine 33(5), 2014
PMID: 25444791
Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA., Hum Vaccin Immunother 10(5), 2014
PMID: 24609063
Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
de Boer PT, Crepey P, Pitman RJ, Macabeo B, Chit A, Postma MJ., Value Health 19(8), 2016
PMID: 27987647
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen LA, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M., Pharmacoeconomics 34(12), 2016
PMID: 27647004
Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
Garcia A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R., Hum Vaccin Immunother 12(9), 2016
PMID: 27184622
Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
Jamotte A, Chong CF, Manton A, Macabeo B, Toumi M., BMC Public Health 16(), 2016
PMID: 27449665
A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E., Infect Dis Ther 4(4), 2015
PMID: 26350238
The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
Nagy L, Heikkinen T, Sackeyfio A, Pitman R., Pharmacoeconomics 34(9), 2016
PMID: 27423657
Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
You JH, Ming WK, Chan PK., Hum Vaccin Immunother 11(3), 2015
PMID: 25714506

Retrospective public health impact of a quadrivalent influenza vaccine in the United States.
Crepey P, de Boer PT, Postma MJ, Pitman R., Influenza Other Respir Viruses 9 Suppl 1(), 2015
PMID: 26256294
Examining Ontario's universal influenza immunization program with a multi-strain dynamic model.
Thommes EW, Chit A, Meier GC, Bauch CT., Vaccine 32(39), 2014
PMID: 25024113
4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany.
Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R., BMC Infect. Dis. 14(), 2014
PMID: 24993051
Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.
Ultsch B, Damm O, Beutels P, Bilcke J, Bruggenjurgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O., Pharmacoeconomics 34(3), 2016
PMID: 26477039
Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control.
Van Maanen BM, de Boer PT, Dolk FC, Friedrich AW, Wilschut JC, Pitman R, Postma MJ., Expert Rev Vaccines 16(1), 2016
PMID: 27539516
Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis.
Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M., BMC Med 11(), 2013
PMID: 23800265
Pharmacoeconomics: NICE's approach to decision-making.
Rawlins M, Barnett D, Stevens A., Br J Clin Pharmacol 70(3), 2010
PMID: 20716233
Thresholds for the cost-effectiveness of interventions: alternative approaches.
Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S., Bull. World Health Organ. 93(2), 2014
PMID: 25883405
Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5.
Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M; ISPOR-SMDM Modeling Good Research Practices Task Force., Med Decis Making 32(5), 2012
PMID: 22990086

Hodgson, Lancet Public Heal. [Internet] 6(16), 2017
Is the impact of childhood influenza vaccination less than expected: a transmission modelling study.
Weidemann F, Remschmidt C, Buda S, Buchholz U, Ultsch B, Wichmann O., BMC Infect. Dis. 17(1), 2017
PMID: 28399801
Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, Li Y, Kwindt TL, Mahmud SM, Van Caeseele P, Krajden M, Petric M., J. Infect. Dis. 210(1), 2014
PMID: 24446529
Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type.
McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, Piedra PA, Zimmerman RK, Nowalk MP, Raviotta JM, Jackson ML, Jackson L, Ohmit SE, Petrie JG, Monto AS, Meece JK, Thaker SN, Clippard JR, Spencer SM, Fry AM, Belongia EA., J. Infect. Dis. 211(10), 2014
PMID: 25406334
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.
Lee J, Boutz DR, Chromikova V, Joyce MG, Vollmers C, Leung K, Horton AP, DeKosky BJ, Lee CH, Lavinder JJ, Murrin EM, Chrysostomou C, Hoi KH, Tsybovsky Y, Thomas PV, Druz A, Zhang B, Zhang Y, Wang L, Kong WP, Park D, Popova LI, Dekker CL, Davis MM, Carter CE, Ross TM, Ellington AD, Wilson PC, Marcotte EM, Mascola JR, Ippolito GC, Krammer F, Quake SR, Kwong PD, Georgiou G., Nat. Med. 22(12), 2016
PMID: 27820605
Clinical Characteristics Are Similar across Type A and B Influenza Virus Infections.
Mosnier A, Caini S, Daviaud I, Nauleau E, Bui TT, Debost E, Bedouret B, Agius G, van der Werf S, Lina B, Cohen JM; GROG network., PLoS ONE 10(9), 2015
PMID: 26325069
A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries.
Tafalla M, Buijssen M, Geets R, Vonk Noordegraaf-Schouten M., Hum Vaccin Immunother 12(4), 2016
PMID: 26890005

Kissling, Euro Surv 21(), 2016
Estimating the impact of childhood influenza vaccination programmes in England and Wales.
Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ., Vaccine 26(41), 2008
PMID: 18647634
Estimating the Lineage Dynamics of Human Influenza B Viruses.
Nyirenda M, Omori R, Tessmer HL, Arimura H, Ito K., PLoS ONE 11(11), 2016
PMID: 27829058
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head.
Wiersma LC, Rimmelzwaan GF, de Vries RD., Vaccines (Basel) 3(2), 2015
PMID: 26343187
Influenza B viruses: not to be discounted.
van de Sandt CE, Bodewes R, Rimmelzwaan GF, de Vries RD., Future Microbiol 10(9), 2015
PMID: 26357957
Influenza B vaccine lineage selection--an optimized trivalent vaccine.
Mosterin Hopping A, Fonville JM, Russell CA, James S, Smith DJ., Vaccine 34(13), 2016
PMID: 26896685
The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study.
van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ., PLoS ONE 6(3), 2011
PMID: 21399678

Impact of influenza on health-related quality of life among confirmed (H1N1)2009 patients.
Hollmann M, Garin O, Galante M, Ferrer M, Dominguez A, Alonso J., PLoS ONE 8(3), 2013
PMID: 23555979
Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study.
Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ, Ferguson N, Goonetilleke N, Harvey G, Kovar J, Lim MS, McMichael A, Millett ER, Nguyen-Van-Tam JS, Nazareth I, Pebody R, Tabassum F, Watson JM, Wurie FB, Johnson AM, Zambon M; Flu Watch Group., Lancet Respir Med 2(6), 2014
PMID: 24717637
Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study.
Milne GJ, Halder N, Kelso JK, Barr IG, Moyes J, Kahn K, Twine R, Cohen C., Influenza Other Respir Viruses 10(4), 2016
PMID: 26663701
Adjuvants in influenza vaccines.
Tetsutani K, Ishii KJ., Vaccine 30(52), 2012
PMID: 23084848
Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines.
Subramanian R, Graham AL, Grenfell BT, Arinaminpathy N., PLoS Comput. Biol. 12(12), 2016
PMID: 27977667


Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®


PMID: 28613092
PubMed | Europe PMC

Suchen in

Google Scholar